Objective To evaluate the effect of different early nutrition support on nutritional status,immune function and stress condition in patients with severe craniocerebral trauma.Methods 90 postoperative patients with severe craniocerebral trauma were randomly divided into standard EN group,immune EN group and TPN group,30 cases in each group.Blood samples were obtained for measurement nutritional status,immune function and stress conditionin in patients before treatment and the first,seventh and twenty first day after surgery.Results Nutritional status,immune function and stress condition of patients in immune EN group improved significantly after seven days.Nutritional status,humoral immune function and stress condition of patients in standard EN group also improved.After 21days,nutritional status,humoral immune function and stress condition of patients in TPN group improved (P ＜ 0.05 or P ＜ 0.01).Conclusion Early immune EN nutrition support of patients with severe craniocerebral trauma can improve nutritional status,immune function and stress condition and maybe the best nutrition support method.

Objective:To analyze the clinical efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced NSCLC.Methods:We collected 23 cases of NSCLC advanced patients, who were treated in the affiliated Cancer Hospital of Guangzhou Medical University from January 2015 to March 2020. And these 23 cases of patients with first-generation EGFR-TKIs resistance were treated with the third-generation EGFR-TKI drugs. We analyzed their clinicopathological characteristics, studied their therapeutic effects, and followed up their progression-free survival (PFS).Results:It is showed that 16 of 23 cases (69.56%) were got local progression and 7 of 23 cases (31.43%) were found with systemic progression. Briefly, the median PFS of the 23 patients was 17.5 months. A total of 7 cases occurred rashes after taking EGFR-TKI, and 3 cases got abnormal liver function. Fortunately, they were all improved after symptomatic treatments. Additionally, no bone marrow suppression (granulocytes, neutropenia, thrombocytopenia, anemia) and digestive tract reactions (nausea, vomiting, diarrhea) were occurred in 23 cases of NSCLC patients. The mental and physical improvement of EGFR-TKI in the third generation of 19 patients was more obvious than that in the first generation of EGFR-TKI. Among them, 15 cases showed more obvious lesion shrinkage after third-generation EGFR-TKI treatment. 4 patients with GGO had cleaner disappearance than that of the first-generation EGFR-TKI.Conclusions:Compared with traditional chemotherapy, the first-generation EGFR-TKI resistance treatment with three-generation EGFR-TKI treatment has better efficacy with reduced toxic and side effects, and significantly improved the life quality of advanced NSCLC patients.